AbbVie's telisotuzumab adizutecan receives two FDA breakthrough therapy designations for CRC and NSCLC
ABBV•AbbVie said the FDA granted telisotuzumab adizutecan two breakthrough therapy designations, for colorectal cancer and non-small cell lung cancer.
1. FDA designations
AbbVie said its telisotuzumab adizutecan, also called temab-a, received two FDA breakthrough therapy designations for CRC and NSCLC.
